Cover Image
市場調查報告書

Integrin Alpha 4:開發中產品分析

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 364858
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
Integrin Alpha 4:開發中產品分析 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2018
出版日期: 2018年01月18日 內容資訊: 英文 75 Pages
簡介

本報告提供以Integrin Alpha 4為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Integrin Alpha 4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Antisense Therapeutics Limited
  • Atox Bio Ltd.
  • Biogen, Inc.
  • BioMAS Ltd.
  • 第一三共
  • EA Pharma Co Ltd
  • Protagonist Therapeutics Inc.
  • 武田藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1249TDB

Summary:

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 3 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Respiratory, Cardiovascular, Genetic Disorders, Ophthalmology and Toxicology which include indications Ulcerative Colitis, Asthma, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Autoimmune Disorders, Celiac Disease, Chemotherapy Effects, Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Melanoma, Multiple Sclerosis, Paraneoplastic Syndrome and Relapsing Remitting Multiple Sclerosis (RRMS).

The latest report Integrin Alpha 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
    • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Antisense Therapeutics Ltd
    • Biogen Inc
    • BioMAS Ltd
    • Daiichi Sankyo Co Ltd
    • EA Pharma Co Ltd
    • Immunwork Inc
    • Morphic Therapeutic Inc
    • Protagonist Therapeutics Inc
    • Takeda Pharmaceutical Co Ltd
    • Viriom Inc
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
    • abrilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATL-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carotegrast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ET-3764 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • natalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TE-5232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vedolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 04, 2018: Protagonist Therapeutics Granted New US Patent for Peptide Drug Candidate PTG-100
      • Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
      • Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update
      • Nov 09, 2017: New Post-Hoc Analysis Evaluating Deep Remission with Entyvio (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as "Poster of Distinction" at AIBD 2017 Annual Conferenc
      • Nov 01, 2017: Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
      • Oct 30, 2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting
      • Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update
      • Oct 16, 2017: New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio (vedolizumab), Particularly in Biologic-Naive Patients
      • Oct 02, 2017: Antisense Therapeutics Provides Update on Multiple Sclerosis Drug Candidate ATL1102
      • Sep 12, 2017: Antisense Therapeutics Announces Update on ATL1102
      • Aug 22, 2017: Takeda Submits a New Drug Application for Vedolizumab for the Treatment of Moderately to Severely Ulcerative Colitis in Japan
      • Jul 27, 2017: Antisense Therapeutics Provides Phase IIb Trial Update on ATL1102 for Multiple Sclerosis
      • Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy
      • Jun 26, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA
      • Jun 16, 2017: Positive effects seen with ATL1102 on Multiple Sclerosis "Black Hole" brain lesions
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Amgen Inc, H1 2018
  • Pipeline by Antisense Therapeutics Ltd, H1 2018
  • Pipeline by Biogen Inc, H1 2018
  • Pipeline by BioMAS Ltd, H1 2018
  • Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Pipeline by EA Pharma Co Ltd, H1 2018
  • Pipeline by Immunwork Inc, H1 2018
  • Pipeline by Morphic Therapeutic Inc, H1 2018
  • Pipeline by Protagonist Therapeutics Inc, H1 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
  • Pipeline by Viriom Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top